ARLINGTON, Va., September 29, 2023 — People with intermediate risk, localized prostate cancer can be treated as effectively using fewer and higher doses of radiation therapy delivered over five treatment sessions as they can with lower doses delivered over several weeks, a new phase III randomized trial suggests. The findings, which are the latest from a series of studies investigating the benefits of stereotactic body radiation therapy (SBRT) for people diagnosed with prostate cancer, will be presented Monday at the American Society for Radiation Oncology (ASTRO) Annual Meeting .

https://www.miragenews.com/research-shortened-radiation-ups-cure-rate-for-1095027/

#miragenews